Randomized controlled trial demonstrates robust osteoinduction via recombinant bone morphogenic protein 2 in irradiated tissue, highlighting potential utility in head and neck reconstruction.
OBJECTIVE: To prove the efficacy of bone morphogenic protein as an osteoinductive agent in irradiated tissue. DESIGN: Prospective randomized controlled trial designed to test the effectiveness of recombinant bone morphogenic protein 2 (rBMP-2) combined with solid hydroxyapatite disks in an irradiated tissue bed. SUBJECTS: Eighteen adult, male, white New Zealand rabbits weighing 3.0 to 3.5 kg. INTERVENTION: The rabbits were randomly divided, with 9 receiving radiation treatment and 9 receiving no radiation treatment. Each animal underwent implantation of 2 hydroxyapatite disks onto the snout at 9 weeks following radiation treatment. One disk was impregnated with rBMP-2 and the other with buffer only. The animals were killed at 3, 6, or 20 weeks after implantation for analysis. RESULTS: Histological analysis demonstrated that rBMP-2 was equally effective as an osteoinductive agent in the irradiated and nonirradiated tissue. We also found significantly increased new bone formation in the rBMP-2 group vs the buffer group. CONCLUSIONS: This study supports the potential clinical utility of rBMP-2 and solid hydroxyapatite in irradiated tissue beds. These findings have interesting implications for patients with head and neck cancer who have undergone radiation therapy and need bony reconstruction.
No takes yet. Share an insight, caveat, or question.
Howard et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: